Redeye comments on Annexin's Q2 report and recent events in the company. We note that interest in Annexin has increased rapidly lately following a strong outcome in the rights issue and upcoming phase II topline data in RVO with its drug candidate ANXV - and we expect an eventful summer/autumn ahead for the company.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/